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Background: The benefit of drug-eluting stents (DES) compared with bare metal stents (BMS) in saphenous vein graft (SVG) intervention remains 
controversial.
Methods: We analyzed data from the multicenter EVENT registry to compare 1-year clinical outcomes among 684 patients who underwent SVG 
intervention using either DES (n=515) or BMS (n=169). The primary endpoint was major adverse cardiovascular events (MACE), a composite of 
death, MI, and target lesion revascularization (TLR), between discharge and 1-year follow-up.
Results: Baseline characteristics were similar except DES patients were less likely to be male, had a lower incidence of angiographic thrombus, 
and were less likely to be treated with an embolic protection device. Total stent length was longer and maximum balloon diameter was smaller 
among DES patients as well. In-hospital outcomes were similar. After propensity score stratification to adjust for differences between groups, the 
adjusted risk of 1-year MACE was lower with DES than with BMS (adjusted HR 0.56, p=0.003) with similar adjusted hazard ratios for each endpoint 
component, including TLR. This reduction in MACE for DES patients persisted after excluding in-hospital events and analyzing only outcomes from 
hospital discharge to one year (adjusted HR 0.48, p<0.01).
Conclusions: SVG intervention with DES compared to BMS resulted in less MACE at one year with no evidence of increased complications or 
mortality. 
Unadjusted Event Rate, DES
Unadjusted Event Rate, 
BMS
Adjusted Hazard Ratio (HR) 
(95% CI)
Multivariate P- value
Out-of-Hospital:
MACE (Death/MI/TLR) 10.3% 13.8% 0.48 (0.27-0.84) <0.01
Death 1.0% 2.5% 0.49 (0.14-1.74) 0.34
MI 3.5% 5.7% 0.50 (0.20-1.26) 0.14
TLR 8.0% 7.5% 0.68 (0.34-1.37) 0.28
One Year:
MACE (Death/MI/TLR) 17.4% 24.2% 0.56 (0.33-0.79) 0.003
Death/MI 11.7% 19.3% 0.49 (0.29-0.83) 0.008
Death 2.0% 3.7% 0.43 (0.13-1.46) 0.18
TLR 8.4% 7.5% 0.69 (0.33-1.41) 0.30
